Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2021

4 - 8 Jun 2021

Virtual, United States of America

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC...

Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021 ( Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China )

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration...

Dr Michael Morris - Memorial Sloan Kettering Cancer Center and Weill Cornell...

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) ( Dr Michael Morris - Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, USA )

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C...

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )

ASCO 2021: Lung roundup

Dr Luis Raez - Memorial Healthcare System, FL, USA

ASCO 2021: Lung roundup ( Dr Luis Raez - Memorial Healthcare System, FL, USA )

FGFR as a tumour agnostic indicator and its importance in the diagnosis and...

Dr Christophe Massard and Prof Eva Compérat

FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types ( Dr Christophe Massard and Prof Eva Compérat )

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA

ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )

Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative...

Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland

Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy ( Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland )

COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory...

Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA

$COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )$

Latest updates in exon 20 insertions focusing on targeted therapies, novel...

Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )

COVID-19 and cancer: Highlights from ASCO 2021

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

COVID-19 and cancer: Highlights from ASCO 2021 ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

Efficacy and safety of tisagenlecleucel in adult patients with relapsed...

Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA

$Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )$

First results of a head-to-head trial of acalabrutinib versus ibrutinib in...

Dr John Byrd - The Ohio State University, Columbus, USA

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )

Breast cancer roundup from ASCO 2021

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

OncoAlert and ecancer ASCO roundup - Day 4 and 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed...

Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake...

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC ( Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake City, USA )

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Developments in metastatic hormone-sensitive prostate cancer

Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura...

Developments in metastatic hormone-sensitive prostate cancer ( Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria Krabbe )

Marizomib in combination with temozolomide-based radiochemotherapy for newly...

Dr Patrick Roth - University Hospital Zurich, Zurich, Switzerland

Marizomib in combination with temozolomide-based radiochemotherapy for newly diagnosed glioblastoma ( Dr Patrick Roth - University Hospital Zurich, Zurich, Switzerland )

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris...

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC ( Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, France )

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC

Dr Christina Baik - University of Washington School of Medicine, Seattle, USA

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in...

Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )

IMpower010: Atezolizumab versus best supportive care after adjuvant...

Prof Heather Wakelee - Stanford University, Stanford, USA

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC ( Prof Heather Wakelee - Stanford University, Stanford, USA )

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival...

Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes ( Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA...

Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )

Adjuvant chemo following chemoradiation as treatment for locally advanced...

Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia

Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone ( Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia )

Tislelizumab in oesophageal cancer after systemic therapy

Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA

Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with...

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo...

Dr Joshua Sabari and Dr Anna Minchom

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal...

Prof Daniel Catenacci - University of Chicago, Chicago, USA

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )

Clinical trials participation is directly influenced by the information...

Dr Daniel Vorobiof - Belong.Life, New York, USA

Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with...

Dr Jonathan Spicer - McGill University, Montreal, Canada

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )

Incidence and trends of HPV-related cancers in the United States

Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Incidence and trends of HPV-related cancers in the United States ( Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Dr Neal Shore and Prof Oliver Sartor

ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )

mCRPC: Latest developments in diagnostics and combination therapies

Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for...

Dr Ian Chau - The Royal Marsden, London, UK

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau - The Royal Marsden, London, UK )

ASCO 2021: Renal cancer roundup

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

More from ecancer